The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Xenon Pharmaceuticals Inc shares valued at $1,777,093 were sold by MORTIMER IAN on Jan 02 ’26. At $44.43 per share, MORTIMER IAN sold 40,000 shares. The insider’s holdings dropped to 6,000 shares worth approximately $0.25 million following the completion of this transaction.
Also, IAN MORTIMER purchased 40,000 shares, netting a total of over 1,777,166 in proceeds.
Before that, MORTIMER IAN had sold 14,375 shares from its account. In a trade valued at $647,306, the PRESIDENT & CEO traded Xenon Pharmaceuticals Inc shares for $45.03 each. Upon closing the transaction, the insider’s holdings decreased to 14,375 shares, worth approximately $0.7 million.
Analysts at Chardan Capital Markets started covering the stock with ‘”a Buy”‘ outlook in a report released in early May. As of February 11, 2025, Deutsche Bank has initiated its “Buy” rating for XENE.
Analyzing XENE Stock Performance
On last trading session, Xenon Pharmaceuticals Inc [NASDAQ: XENE] rose 3.02% to $41.58. The stock’s lowest price that day was $39.98, but it reached a high of $42.0 in the same session. During the last five days, there has been a drop of approximately -1.28%. Over the course of the year, Xenon Pharmaceuticals Inc shares have jumped approximately 8.71%.
Is Xenon Pharmaceuticals Inc subject to short interest?
Stocks of Xenon Pharmaceuticals Inc saw a sharp rise in short interest on 2025-12-31 jumping by 38107.0 shares to 5.93 million. Data from Yahoo Finance shows that the short interest on 2025-11-28 was 5.89 million shares. A jump of 0.64% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 7.68 of the overall float, the days-to-cover ratio (short ratio) jumped to 7.68.
Which companies own the most shares of Xenon Pharmaceuticals Inc (XENE)?
In terms of Xenon Pharmaceuticals Inc share price expectations, FactSet research, analysts set an average price target of 55 in the next 12 months, up nearly 36.27% from the previous closing price of $40.36. Analysts anticipate Xenon Pharmaceuticals Inc stock to reach 58 by 2026, with the lowest price target being 44. In spite of this, 10 analysts ranked Xenon Pharmaceuticals Inc stock as Buy at the end of 2026. On October 01, 2024, H.C. Wainwright assigned a price target of “a Buy” to the stock and initiated coverage with a $53.
